New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 19, 2014
10:13 EDTOCUL, RPTP, NADL, SCL, PSG, MRKT, SAFM, JAZZ, FIATY, BITA, INNL, FARO, ATHM, GMED, LOCOOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Autohome (ATHM) initiated with a Buy at Brean Capital... Bitauto (BITA) initiated with a Buy at Brean Capital... El Pollo Loco (LOCO) initiated with a Hold at Jefferies... FARO Technologies (FARO) initiated with an Overweight at Stephens... Fiat (FIATY) initiated with an Underperform at Credit Suisse... Globus Medical (GMED) initiated with a Buy at Gabelli... Innocoll (INNL) initiated with a Buy at Stifel... Jazz Pharmaceuticals (JAZZ) initiated with an Overweight at JPMorgan... Markit (MRKT) initiated with an Outperform at Credit Suisse... North Atlantic Drilling (NADL) initiated with a Neutral at Goldman... Ocular Therapeutix (OCUL) initiated with an Outperform at Cowen... Performance Sports Group (PSG) initiated with an Overweight at Morgan Stanley... Raptor Pharmaceuticals (RPTP) coverage transferred with an Outperform at Cowen... Sanderson Farms (SAFM) initiated with a Buy at Sidoti... Stepan Company (SCL) initiated with a Hold at KeyBanc.
News For ATHM;BITA;LOCO;FARO;FIATY;GMED;INNL;JAZZ;MRKT;NADL;OCUL;PSG;RPTP;SAFM;SCL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 31, 2015
07:28 EDTJAZZJazz Pharmaceuticals price target raised to $220 from $201 at Leerink
Subscribe for More Information
July 30, 2015
16:50 EDTGMEDGlobus Medical riases FY15 EPS view by 2c to $1.04, consensus $1.04
Raises FY15 revenue guidance by $10M to $524M, consensus $518.49M.
16:49 EDTGMEDGlobus Medical reports Q2 EPS 25c, consensus 25c
Subscribe for More Information
15:00 EDTMRKTNASDAQ, Markit are potential suitors for IDC, WSJ reports
Nasdaq (NDAQ) and Markit (MRKT), in addition to some private equity firms, are potential bidders for financial data provider Interactive Data Corp., says the Wall Street Journal. A deal for IDC, which is pursuing a possible sale or IPO, could value the company at over $5B, including debt, added the Wall Street Journal. Reference Link
14:43 EDTMRKTNASDAQ, Markit have expressed interest in IDC, WSJ reports
Subscribe for More Information
10:00 EDTFAROOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:08 EDTFAROFARO Technologies upgraded to Hold from Sell at Noble Financial
July 29, 2015
16:56 EDTFAROFARO Technologies reports Q2 EPS 24c, consensus 24c
Subscribe for More Information
16:05 EDTFAROFARO Technologies appoints Laura A. Murphy as CFO
Subscribe for More Information
15:52 EDTJAZZUSPTO review of Jazz patents negative but not unexpected, says BMO Capital
Subscribe for More Information
15:46 EDTJAZZJazz Pharmaceuticals says USPTO moving forward with review of Xyrem patents
Subscribe for More Information
July 24, 2015
11:59 EDTJAZZLeerink's specialty pharma/generics analyst has analyst/industry conference call
Specialty Pharmaceuticals/Generics Analyst Gerberry discusses the strengths and weaknesses of TEVA’s preliminary responses to the IPR challenge on Copaxone 40mg, the likely outcomes for the Copaxone 40mg patent challenge and the perspectives on recent updates in the Jazz Pharmaceuticals' Xyrem patent case on an Analyst/Industry conference call to be held on July 27 at 11 am.
July 22, 2015
07:06 EDTSCLStepan Company remain 'on track' to re-establish earnings momentum for FY15
CEO Quinn Stepan commented, "In the second half, Surfactant earnings should benefit from new commodity laundry volumes in North and Latin America, continued diversification of our business in Europe as well as contributions from improved operations and our efficiency program. We expect continued Polymer income growth in 2015 driven by higher polyol volumes used in rigid insulation and metal panels. Our construction projects to add polyol capacity in China and Poland are progressing and both should start production in 2016."
07:06 EDTSCLStepan reports Q2 Surfactant sales volumes up 1%, operating income $24.2M
Reports Q2 Polymer sales volumes up 3%, operating income $23.4M. Reports Q2 Surfactants revenue down 10% to $299.74M and Q2 Polymer sales down 10% to $133.61M.
07:04 EDTSCLStepan Company reports Q2 adjusted EPS 91c, consensus 94c
Subscribe for More Information
July 20, 2015
10:26 EDTJAZZLeerink's specialty pharma/generics analyst has analyst/industry conference call
Specialty Pharmaceuticals / Generics Analyst Gerberry, along with MEDACorp Specialists Michael Belliveau, PhD and Shashank Upadhye, JD, discuss the strengths and weaknesses of TEVA's preliminary responses to the IPR challenge on Copaxone 40mg, the likely outcomes for the Copaxone 40mg patent challenge and perspectives on recent updates in the JAZZ Xyrem patent case on an Analyst/Industry conference call to be held on July 22 at 2 pm.
10:17 EDTRPTPHigh option volume stocks
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use